Sudeep Pharma Limited
Sudeep Pharma Limited manufactures and sells excipients and specialty ingredients for the pharmaceutical, food, and nutrition industries in United States, Europe, United Kingdom, and Latin America. The company provides mineral salts, such as calcium, zinc, iron, potassium, magnesium, sodium, and copper to a range of health-focused applications; and calcium carbonate, which is used as an active pharmaceutical ingredient for various therapeutic applications. It also offers micronutrient premixes, encapsulated ingredients, liposomal and spray-dried formats, granulated minerals, and triturated blends to meet the needs across functional foods, dietary supplements, infant and clinical nutrition, fast-moving consumer goods, and convenience food formulations. In addition, the company is involved in manufacturing, developing, buying, selling, importing, exporting, trading, agency, testing, distributing, consigning, stocking, registering, packing, marketing, refining, and processing of pharmaceuticals, nutraceutical and nutrition products, food ingredients, mineral and vitamin blends, or premixes for infant, human and animal nutrition, and other chemical and healthcare products. Sudeep Pharma Limited was incorporated in 1989 and is based in Vadodara, India.
Valuation
Profitability
Returns
Solvency
AI Summary
Indian StockRule-based from financial data. Not advice.
Historically, Jun has averaged the highest return (+26.2%); Dec the lowest (-22.1%).
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | +0.9%Neutral MonthJan 2026: +0.95% | +5.1%Positive MonthFeb 2026: +5.13% | -7.4%Negative MonthMar 2026: -7.35% | +19.5%Positive MonthApr 2026: +19.54% | -5.1%Negative MonthMay 2026: -5.15% | +26.2%Positive MonthJun 2026: +26.18% | +1.7%*Neutral MonthJul 2026: +1.73% | β | β | β | β | β |
| 2025 | β | β | β | β | β | β | β | β | β | β | β | -22.1%Negative MonthDec 2025: -22.13% |
| AvgΒ±SD |
Each cell is the percentage change in closing price from the end of the prior month to the end of this month. The bottom row shows the average return for that calendar month across the selected years, plus or minus one standard deviation β the range that historically contained roughly two-thirds of outcomes. Past monthly patterns are not a forecast of future returns.
This aggregates every month by calendar position β all Januaries together, all Februaries together, and so on β to show whether a given month has leaned positive or negative historically. βSimpleβ counts each month as +1 or β1. βWeightedβ gives larger moves more influence: +2 above +10%, β2 below β10%. With only 2 years of history for this asset, each monthβs score reflects a small number of observations β read it as a historical tendency, not a reliable seasonal pattern.
This tracks a running tally across the assetβs full price history: each month adds or subtracts based on whether it was positive or negative. A rising line means more positive months than negative so far; a flattening or falling line means recent months have leaned negative. This measures historical month-to-month consistency, not expected future performance.
Year-to-date return is calculated by dividing each dayβs closing price by the price on January 1st of that year (or the assetβs first available price if it began trading mid-year). The custom average line shows the mean YTD return at each calendar day across the selected years. The standard deviation band shows the range within which returns have historically fallen β at 1 SD, roughly two-thirds of years; at 2 SD, roughly 95%. Past year-to-date patterns do not predict future returns. The average and standard deviation band are computed from the year set chosen in βAverage fromβ, which is independent of which year lines are displayed. The current in-progress year is excluded from these calculations, since a partial year is not comparable to complete ones. Election-cycle groupings follow the US presidential calendar and are offered only for US and crypto assets.
Historical Performance
Revenue, profitability, and cash flow trends (βΉ Crores)
Revenue (10Y)
Operating Income (10Y)
Net Profit (10Y)
Operating Margin % (10Y)
Dividend Payout % (10Y)
Free Cash Flow (10Y)
Growth Summary
Latest fiscal year: Mar 2025
Historical Growth
Year-by-year revenue, profitability, and cash flow (βΉ Crores, last 10 years)
| Year | Revenue | Op. Income | Net Profit | CFO | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|---|
| Mar 2025 | βΉ357.00 Cr | β | βΉ96.00 Cr | β | β | 22.4% | 3.8% | -2.0% |
| Mar 2024 | βΉ344.00 Cr | β | βΉ98.00 Cr | β | β | 29.3% | -14.9% | 46.3% |
| Mar 2023 | βΉ404.00 Cr | β | βΉ67.00 Cr | β | β | 28.4% | 17.1% | 28.8% |
| Mar 2022 | βΉ345.00 Cr | β | βΉ52.00 Cr | β | β | 31.0% | 58.3% | 48.6% |
| Mar 2021 | βΉ218.00 Cr | β | βΉ35.00 Cr | β | β | 30.2% | β | β |
Financial Statements
Income statement, balance sheet, and cash flow (βΉ Crores, as reported)
Consolidated Figures in USD Millions.
| Unnamed: 0 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|
| Revenue / Net Sales | 218 | 345 | 404 | 344 | 357 |
| Total Expenses | 172 | 277 | 315 | 211 | 224 |
| EBIT / Operating Profit | 46 | 68 | 89 | 133 | 133 |
| OPM % | 21% | 20% | 22% | 39% | 37% |
| Other Income | 4 | 8 | 11 | 8 | 8 |
| Finance Costs | 1 | 2 | 5 | 4 | 6 |
| Depreciation & Amortisation | 4 | 4 | 5 | 5 | 6 |
| Profit Before Tax | 45 | 70 | 91 | 132 | 129 |
| Tax % | 22% | 26% | 26% | 26% | 26% |
| Net Profit / PAT | 35 | 52 | 67 | 98 | 96 |
| EPS (βΉ) | 248.31 | 371.23 | 476.69 | 696.05 | 9.85 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% |
Peer Comparison
Healthcare sector peers, ranked by market cap
| Company | Market Cap | Revenue | P/E | P/B | EV/EBITDA | Rev G 1Y |
|---|---|---|---|---|---|---|
| Sudeep Pharma Limitedthis co. | βΉ7.03 K Cr | βΉ357.00 Cr | 73.50 | 0.00 | 49.86 | 3.8% |
| Sun Pharmaceutical Industries Ltd. | βΉ4.15 L Cr | βΉ23.00 K Cr | 88.70 | 17.43 | 72.30 | 13.5% |
| Divi's Laboratories Ltd. | βΉ1.71 L Cr | βΉ9.20 K Cr | 67.90 | 11.13 | 67.21 | 20.0% |
| Torrent Pharmaceuticals Ltd. | βΉ1.33 L Cr | βΉ9.68 K Cr | 62.50 | 15.76 | 45.64 | 13.5% |
| Cipla Ltd. | βΉ1.17 L Cr | βΉ19.05 K Cr | 22.50 | 3.51 | 19.33 | 14.9% |
| Apollo Hospitals Enterprises Ltd. | βΉ1.05 L Cr | βΉ8.20 K Cr | 75.00 | 11.28 | 54.44 | 12.8% |
| Max Healthcare Institute Limited | βΉ1.00 L Cr | βΉ2.66 K Cr | 144.00 | 11.76 | 96.84 | 13.8% |
| Industry Average | β | βΉ3.29 K Cr | 98.63 | 8.11 | 65.50 | 20.2% |
